MAZE

Maze Therapeutics, Inc. MAZE

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,876 of 2,925

Why it scores 10Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$0

Quarter to Jun 30

Net income

$-44.73M

Quarter to Jun 30

Free cash flow

$-15.16M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.75B total
Frazier Life Sciences Management, L.P.
$150.18M+10.2%
TRV GP IV, LLC
$133.50M0.0%
ARCH Venture Management, LLC
$122.98M0.0%
Deep Track Capital, LP
$111.38M+7.3%
BlackRock, Inc.
$104.52M+36.3%
Jupiter Topco LLC
$101.76M--
T. Rowe Price Investment Management, Inc.
$77.69MNew
Logos Global Management LP
$57.74M+56.7%
VANGUARD CAPITAL MANAGEMENT LLC
$53.06M+23.9%
a16z Capital Management, L.L.C.
$50.79M0.0%
VR Adviser, LLC
$47.80M0.0%
Alphabet Inc.
$41.44M0.0%
BRAIDWELL LP
$34.02MNew
FARALLON CAPITAL MANAGEMENT LLC
$33.06M+197.0%
FMR LLC
$31.54M+22.3%
General Catalyst Group Management, LLC
$30.91M0.0%
STATE STREET CORP
$29.77M+56.7%
DRIEHAUS CAPITAL MANAGEMENT LLC
$28.49M+50.1%
TRV GP V, LLC
$28.37M0.0%
JPMORGAN CHASE & CO
$28.00M+1549.4%
MARSHALL WACE, LLP
$27.29M+194.4%
GEODE CAPITAL MANAGEMENT, LLC
$25.61M+43.0%
CITADEL ADVISORS LLC
$25.44M+9.9%
Casdin Capital, LLC
$25.18M+11.2%
ArrowMark Colorado Holdings LLC
$22.90M0.0%
See all 162 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MAZE

Earnings Per Share

13fpro.ai/company/MAZE

Loading ratio trend…

MAZE key financials by period

Reported revenue, net income and operating margin by fiscal year, from Maze Therapeutics, Inc.'s annual filings on SEC EDGAR.

Maze Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2024$167.5M$52.2M34.4%
Source: MAZE filings on SEC EDGAR →

Companies similar to MAZE

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

MAZE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Maze Therapeutics, Inc. (MAZE): stock profile, AI score and financials

Maze Therapeutics, Inc. (MAZE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MAZE at 9.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,876 of 2,925 stocks — the bottom half of the AI-ranked universe. MAZE scores in the top quartile across institutional flow (93.1). Areas of concern include free cash flow (1.0) and revenue scale (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Maze Therapeutics, Inc. reports net income of $-44.7M, free cash flow of $-15.2M. Top institutional holders of MAZE by reported 13-F value include Frazier Life Sciences Management, L.P., TRV GP IV, ARCH Venture Management, based on the most recent SEC filings. MAZE trades on the Nasdaq exchange and files with the SEC under CIK 1842295. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MAZE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Maze Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1842295 →